Overview

Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients

Status:
Terminated
Trial end date:
2017-05-25
Target enrollment:
Participant gender:
Summary
Patients who have undergone the Fontan procedure (a congenital heart surgery) may develop complications many years after their operation. Studies have shown that some of these patients develop an ongoing inflammatory state, which may be the cause of these late complications. Aspirin is a common over the counter anti-inflammatory medication used for many other chronic diseases. This study may help determine if aspirin therapy can limit the inflammation seen in Fontan patients and prevent these late complications.
Phase:
Phase 4
Details
Lead Sponsor:
University of Michigan
Treatments:
Anti-Inflammatory Agents
Aspirin